AP2855A - Anti-retroviral combination - Google Patents

Anti-retroviral combination

Info

Publication number
AP2855A
AP2855A AP2010005325A AP2010005325A AP2855A AP 2855 A AP2855 A AP 2855A AP 2010005325 A AP2010005325 A AP 2010005325A AP 2010005325 A AP2010005325 A AP 2010005325A AP 2855 A AP2855 A AP 2855A
Authority
AP
ARIPO
Prior art keywords
retroviral combination
retroviral
combination
Prior art date
Application number
AP2010005325A
Other languages
English (en)
Other versions
AP2010005325A0 (en
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54289250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2855(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of AP2010005325A0 publication Critical patent/AP2010005325A0/en
Application granted granted Critical
Publication of AP2855A publication Critical patent/AP2855A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/78—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling
    • B29C48/80—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling at the plasticising zone, e.g. by heating cylinders
    • B29C48/83—Heating or cooling the cylinders
    • B29C48/832—Heating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
AP2010005325A 2007-12-24 2008-12-24 Anti-retroviral combination AP2855A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2538MU2007 2007-12-24
PCT/GB2008/004291 WO2009081174A2 (en) 2007-12-24 2008-12-24 Anti - retroviral combination

Publications (2)

Publication Number Publication Date
AP2010005325A0 AP2010005325A0 (en) 2010-08-31
AP2855A true AP2855A (en) 2014-02-28

Family

ID=54289250

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2013007064A AP2013007064A0 (en) 2007-12-24 2008-12-24 Anti-retroviral combination
AP2010005325A AP2855A (en) 2007-12-24 2008-12-24 Anti-retroviral combination

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AP2013007064A AP2013007064A0 (en) 2007-12-24 2008-12-24 Anti-retroviral combination

Country Status (20)

Country Link
US (1) US9339470B2 (xx)
EP (2) EP2242482B1 (xx)
JP (2) JP2011507940A (xx)
CN (2) CN101925350B (xx)
AP (2) AP2013007064A0 (xx)
AT (1) ATE555778T1 (xx)
AU (1) AU2008339633A1 (xx)
BR (1) BRPI0819534A2 (xx)
CA (1) CA2710605C (xx)
DK (1) DK2242482T3 (xx)
ES (2) ES2385819T3 (xx)
GT (1) GT200800303A (xx)
HK (1) HK1149905A1 (xx)
JO (2) JO2814B1 (xx)
MX (1) MX2010007083A (xx)
PA (1) PA8809601A1 (xx)
PE (2) PE20091530A1 (xx)
RU (2) RU2531089C2 (xx)
WO (1) WO2009081174A2 (xx)
ZA (1) ZA201004505B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
MX2012008627A (es) 2010-01-28 2012-09-21 Mapi Pharma Ltd Proceso para la preparacion de darunavir e intermedios de darunavir.
CN103347539A (zh) * 2010-12-22 2013-10-09 范斯坦医药研究院 使用hiv蛋白酶抑制剂治疗系统性红斑狼疮的方法
US20140142070A1 (en) * 2011-07-07 2014-05-22 Janssen R&D Ireland Darunavir combination formulations
EA026588B1 (ru) * 2011-07-07 2017-04-28 Янссен Сайенсиз Айрлэнд Юси Составы на основе дарунавира
CA2871794A1 (en) * 2012-05-03 2013-11-07 Cipla Limited Antiretroviral composition
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
WO2015028875A2 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
WO2015155673A1 (en) 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
US11045423B2 (en) * 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
RU2760129C1 (ru) * 2020-12-04 2021-11-22 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального антиретровирусного терапевтического средства

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084529A1 (en) * 2003-08-28 2005-04-21 Joerg Rosenberg Solid pharmaceutical dosage form
WO2006055455A1 (en) * 2004-11-16 2006-05-26 Boehringer Ingelheim International, Gmbh Method for treating hiv infection through co-administration of tipranavir and darunavir
WO2006091529A2 (en) * 2005-02-23 2006-08-31 Abbott Laboratories A solid pharmaceutical dosage formulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
JP2994031B2 (ja) 1988-12-20 1999-12-27 クラリティ テクノロジーズ インコーポレイテッド Ｈｉｖ−１又はｈｉｖ−２抗体の存在又は量の確定方法、免疫特異的試薬、合成ペプチド、診断用キット、ｈｉｖ−１又はｈｉｖ−２抗体の調製方法、免疫原及び抗体
WO1990007199A1 (en) 1988-12-20 1990-06-28 Mawzones Developments Limited Focussing device for a microwave antenna
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein
ES2189721T3 (es) 1992-12-29 2003-07-16 Abbott Lab Inhibidores de proteasa retroviral.
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
RU2275361C3 (ru) 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
DE602005009366D1 (de) * 2004-07-08 2008-10-09 Tibotec Pharm Ltd Kombination aus tenofovir, ritonavir und tmc114
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR20080091767A (ko) * 2005-12-14 2008-10-14 씨아이피엘에이 엘티디. (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084529A1 (en) * 2003-08-28 2005-04-21 Joerg Rosenberg Solid pharmaceutical dosage form
WO2006055455A1 (en) * 2004-11-16 2006-05-26 Boehringer Ingelheim International, Gmbh Method for treating hiv infection through co-administration of tipranavir and darunavir
WO2006091529A2 (en) * 2005-02-23 2006-08-31 Abbott Laboratories A solid pharmaceutical dosage formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEKAR V J ET AL: "Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negarive healthy volunteers", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 51, no. 3, 8 January 2007 (2007-01-08), pages 958-961 *

Also Published As

Publication number Publication date
CN101925350A (zh) 2010-12-22
WO2009081174A2 (en) 2009-07-02
JP2011507940A (ja) 2011-03-10
ES2385819T3 (es) 2012-08-01
GT200800303A (es) 2009-09-18
MX2010007083A (es) 2010-10-20
ATE555778T1 (de) 2012-05-15
AP2013007064A0 (en) 2013-08-31
BRPI0819534A2 (pt) 2015-05-26
ZA201004505B (en) 2013-05-29
CN103638032A (zh) 2014-03-19
AP2010005325A0 (en) 2010-08-31
CA2710605C (en) 2017-05-02
JP2015007071A (ja) 2015-01-15
DK2242482T3 (da) 2012-08-06
WO2009081174A3 (en) 2009-08-27
EP2242482B1 (en) 2012-05-02
CN101925350B (zh) 2014-04-30
JO2814B1 (en) 2014-09-15
PA8809601A1 (es) 2009-07-23
ES2674730T3 (es) 2018-07-03
JO3376B1 (ar) 2019-03-13
HK1149905A1 (en) 2011-10-21
US9339470B2 (en) 2016-05-17
RU2010131006A (ru) 2012-02-10
EP2505193A1 (en) 2012-10-03
CA2710605A1 (en) 2009-07-02
AU2008339633A1 (en) 2009-07-02
US20110008429A1 (en) 2011-01-13
RU2675831C2 (ru) 2018-12-25
PE20140926A1 (es) 2014-08-06
RU2014111723A (ru) 2015-10-10
PE20091530A1 (es) 2009-09-25
RU2531089C2 (ru) 2014-10-20
EP2242482A2 (en) 2010-10-27
EP2505193B1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
AP2855A (en) Anti-retroviral combination
ZA201002568B (en) Herbicide-safener combination
GB0706633D0 (en) Combination
IL202616A0 (en) Substituted imidazoheterocycles
ZA201001683B (en) Substituted piperidino-dihydrothienopyrimidines
GB0702456D0 (en) New combination
AP2010005314A0 (en) Nanodispersian
GB0702385D0 (en) New combination
GB0702416D0 (en) New combination
ZA201002562B (en) Combination thepary
ZA201003064B (en) Novel antiretroviral combination
IL200965A0 (en) Substituted tetrahydropyrroloquinolines
EP2134587A4 (en) INTERMEDIATE TRACTION BAR ARRANGEMENT
KG1098C1 (en) Towel-drying construction
AU3606P (en) Jaywick xTriticosecale
AU3595P (en) Goldust Strobilanthes anisophyllus
AU3642P (en) TAS100 Dianella tasmanica
AU3613P (en) LS005A01 Leucospermum cuneiforme
GB0707145D0 (en) Combination therapy - 793
HUP0700365A2 (en) Combination
GB0724260D0 (en) Novel combination
ZA201000435B (en) Substituted imidazoheterocycles
GB0718494D0 (en) MUulti-function extension
GB0715691D0 (en) Hair-we-grwo extension
AU316644S (en) Bed - AP